As described in other cell models [20, 21], we show that PARP1 inhibition triggers AKT activation but disclose the first insight on the role of PARP1/SIRT1 balancing in the control of the AKT/mTOR axis providing a further rationale for the treatment of this aggressive cancer. Here, MTOR is linked to cancer.